-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

Benzinga·08/25/2026 13:59:18
Listen to the news
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.